nach oben

Erschienen in:

22.05.2017 | Original articles

European guidelines on lifestyle changes for management of hypertension

Awareness and implementation of recommendations among German and European physicians

verfasst von: Dr. J. Bolbrinker, L. Zaidi Touis, H. Gohlke, B. Weisser, R. Kreutz

Erschienen in: Herz | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

In the 2013 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension, six lifestyle changes for treatment are recommended for the first time with class I, level of evidence A. We initiated a survey among physicians to explore their awareness and consideration of lifestyle changes in hypertension management.

Methods

The survey included questions regarding demographics as well as awareness and implementation of the recommended lifestyle changes. It was conducted at two German and two European scientific meetings in 2015.

Results

In all, 1064 (37.4% female) physicians participated (806 at the European and 258 at the German meetings). Of the six recommended lifestyle changes, self-reported awareness was highest for regular exercise (85.8%) followed by reduction of weight (66.2%). The least frequently self-reported lifestyle changes were the advice to quit smoking (47.3%) and moderation of alcohol consumption (36.3%). Similar frequencies were observed for the lifestyle changes implemented by physicians in their care of patients.

Conclusion

A close correlation between awareness of guideline recommendations and their implementation into clinical management was observed. European physicians place a stronger emphasis on regular exercise and weight reduction than on the other recommended lifestyle changes. Moderation of alcohol consumption is the least emphasized lifestyle change.

Lim SS, Vos T, Flaxman AD, Danaei G et al (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2224–2260. doi:10.1016/s0140-6736(12)61766-8 CrossRefPubMedPubMedCentral

World Health Organization (2013) WHO. A global brief on hypertension (Silent killer, global public health crisis) Geneva. http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/. Accessed 25 Apr 2016

NCD-RisC Collaboration(NCD-RisC), NRF (2017) Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19,1 million participants. Lancet 389:37–55. doi:10.1016/S0140-6736(16)31919-5 CrossRef

Kannel WB (1996) Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275:1571–1576. doi:10.1001/jama.1996.03530440051036 CrossRefPubMed

MacMahon S, Peto R, Cutler J, Collins R et al (1990) Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335:765–774. doi:10.1016/0140-6736(90)90878-9 CrossRefPubMed

Ettehad D, Emdin CA, Kiran A, Anderson SG et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967. doi:10.1016/s0140-6736(15)01225-8 CrossRefPubMed

Redon J, Mourad JJ, Schmieder RE, Volpe M et al (2016) Why in 2016 are patients with hypertension not 100 % controlled? A call to action. J Hypertens 34:1480–1488. doi:10.1097/hjh.0000000000000988 CrossRefPubMed

Borghi C, Tubach F, De Backer G, Dallongeville J et al (2016) Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study. Int J Cardiol 218:83–88. doi:10.1016/j.ijcard.2016.05.044 CrossRefPubMed

Wang YR, Alexander GC, Stafford RS (2007) Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 167:141–147. doi:10.1001/archinte.167.2.141 CrossRefPubMed

10.

Mancia G, Fagard R, Narkiewicz K, Redon J et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31:1281–1357. doi:10.1097/01.hjh.0000431740.32696.cc CrossRefPubMed

11.

Mancia G, Fagard R, Narkiewicz K, Redon J et al (2014) 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 23:3–16. doi:10.3109/08037051.2014.868629 CrossRefPubMed

12.

Reisin E, Harris RC, Rahman M (2014) Commentary on the 2014 BP guidelines from the panel appointed to the Eighth Joint National Committee (JNC 8). J Am Soc Nephrol 25:2419–2424. doi:10.1681/asn.2014040371 CrossRefPubMedPubMedCentral

13.

Appel LJ (2003) Lifestyle modification as a means to prevent and treat high blood pressure. J Am Soc Nephrol 14:S99–s102CrossRefPubMed

14.

The Treatment of Mild Hypertension Research Group (1991) The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. The Treatment of Mild Hypertension Research Group. Arch Intern Med 151:1413–1423CrossRef

15.

Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D et al (2006) Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 144:485–495. doi:10.7326/0003-4819-144-7-200604040-00007 CrossRefPubMed

16.

Frisoli TM, Schmieder RE, Grodzicki T, Messerli FH (2011) Beyond salt: lifestyle modifications and blood pressure. Eur Heart J 32:3081–3087. doi:10.1093/eurheartj/ehr379 CrossRefPubMed

17.

Sarafidis PA, Georgianos P, Bakris GL (2013) Resistant hypertension – its identification and epidemiology. Nat Rev Nephrol 9:51–58. doi:10.1038/nrneph.2012.260 CrossRefPubMed

18.

Sternlicht H, Bakris GL (2015) Spironolactone for resistant hypertension – hard to resist? Lancet 386:2032–2034. doi:10.1016/s0140-6736(15)00264-0 CrossRefPubMed

19.

German Society of Cardiology, DGK Düsseldorf. https://dgk.org/. Accessed 10 March 2016

20.

German Society of Internal Medicine, DGIM Wiesbaden. http://www.dgim.de/. Accessed 10 March 2016

21.

European Society of Hypertension, ESH Europe. http://www.eshonline.org/. Accessed 10 March 2016

22.

European Society of Cardiology, ESC Europe. https://www.escardio.org/. Accessed 10 March 2016

23.

O’Donnell CJ, Kannel WB (1998) Cardiovascular risks of hypertension: lessons from observational studies. J Hypertens Suppl 16:S3–S7CrossRefPubMed

24.

World Health Organization (2014) Global status report on alcohol and health 2014. http://apps.who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf. Accessed 26 Apr 2016

25.

Puddey IB, Beilin LJ (2006) Alcohol is bad for blood pressure. Clin Exp Pharmacol Physiol 33:847–852. doi:10.1111/j.1440-1681.2006.04452.x CrossRefPubMed

26.

Taylor B, Irving HM, Baliunas D, Roerecke M et al (2009) Alcohol and hypertension: gender differences in dose-response relationships determined through systematic review and meta-analysis. Addiction 104:1981–1990. doi:10.1111/j.1360-0443.2009.02694.x CrossRefPubMed

27.

Groppelli A, Giorgi DM, Omboni S, Parati G et al (1992) Persistent blood pressure increase induced by heavy smoking. J Hypertens 10:495–499. doi:10.1097/00004872-199205000-00014 CrossRefPubMed

28.

Primatesta P, Falaschetti E, Gupta S, Marmot MG et al (2001) Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 37:187–193. doi:10.1161/01.HYP.37.2.187 CrossRefPubMed

29.

Akbartabartoori M, Lean ME, Hankey CR (2005) Relationships between cigarette smoking, body size and body shape. Int J Obes (Lond) 29:236–243. doi:10.1038/sj.ijo.0802827 CrossRef

30.

Halimi JM, Giraudeau B, Vol S, Caces E et al (2002) The risk of hypertension in men: direct and indirect effects of chronic smoking. J Hypertens 20:187–193. doi:10.12691/jfnr-4-11-7 CrossRefPubMed

31.

Auerbach O, Hammond EC, Garfinkel L (1965) Smoking in relation to atherosclerosis of the coronary arteries. N Engl J Med 273:775–779. doi:10.1056/nejm196510072731501 CrossRefPubMed

32.

Elhani S, Cleophas TJ, Atiqi R (2009) Lifestyle interventions in the management of hypertension: a survey based on the opinion of 105 practitioners. Neth Heart J 17:9–12CrossRefPubMedPubMedCentral

33.

Baumann S, Toft U, Aadahl M, Jorgensen T et al (2015) The long-term effect of a population-based life-style intervention on smoking and alcohol consumption. The Inter99 Study – a randomized controlled trial. Addiction 110:1853–1860. doi:10.1111/add.13052 CrossRefPubMed

Titel: European guidelines on lifestyle changes for management of hypertension
Awareness and implementation of recommendations among German and European physicians
verfasst von: Dr. J. Bolbrinker
L. Zaidi Touis
H. Gohlke
B. Weisser
R. Kreutz
Publikationsdatum: 22.05.2017
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 4/2018
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-017-4575-0

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Prognosis of patients with implanted pacemakers in 4‑year follow-up

Cerebral dopamine neurotrophic factor protects H9c2 cardiomyocytes from apoptosis

Efficacy of RADPAD protective drape during coronary angiography

Chronische Hypoxie – das sind die kardiovaskulären Folgen

CME: Kraftfahreignung bei Herzerkrankungen